Drugs / JNJ-53718678 500 mg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03379675 | Feb 2018 → Nov 2019 | respiratory syncytial virus infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-53718678 500 mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03379675 ↗ |
| Action | Inhibit | “RSV fusion inhibitor rilematovir” PMID 37422079 ↗ Jul 2023 |
| Route | Oral | “JNJ-53718678 oral solution once daily for 7 days” NCT03379675 ↗ |